Intensity Therapeutics Inc. (NASDAQ:INTS) Receives $37.50 Consensus Target Price from Analysts

Shares of Intensity Therapeutics Inc. (NASDAQ:INTS) have received an average rating of “Moderate Buy” from the four research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $37.50.

INTS has been the topic of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Monday, December 22nd. Wall Street Zen raised Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Freedom Capital raised Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 30th.

Intensity Therapeutics Price Performance

Shares of Intensity Therapeutics stock opened at $5.50 on Wednesday. The stock’s 50-day simple moving average is $6.96 and its 200-day simple moving average is $8.87. Intensity Therapeutics has a 52 week low of $4.63 and a 52 week high of $50.00. The company has a market capitalization of $13.97 million, a price-to-earnings ratio of -0.35 and a beta of 3.65. The company has a quick ratio of 5.92, a current ratio of 5.92 and a debt-to-equity ratio of 0.01.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.31) EPS for the quarter. As a group, analysts expect that Intensity Therapeutics will post -1.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Intensity Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after acquiring an additional 201,357 shares during the last quarter. Sentinus LLC grew its stake in shares of Intensity Therapeutics by 630.0% during the second quarter. Sentinus LLC now owns 199,316 shares of the company’s stock valued at $61,000 after buying an additional 172,012 shares during the last quarter. Mesirow Financial Investment Management Inc. grew its stake in shares of Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after buying an additional 51,000 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Intensity Therapeutics during the fourth quarter valued at approximately $26,000. Finally, Corient Private Wealth LLC bought a new position in shares of Intensity Therapeutics during the fourth quarter valued at approximately $41,000. 3.74% of the stock is owned by institutional investors.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.